<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) or spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) is an autosomal dominantly-inherited <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorder</z:e> caused by the over-repetition of a CAG codon in the MJD1 gene </plain></SENT>
<SENT sid="1" pm="."><plain>This expansion translates into a polyglutamine tract that confers a toxic gain-of-function to the mutant protein--ataxin-3, leading to <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> in specific brain regions, with particular severity in the cerebellum </plain></SENT>
<SENT sid="2" pm="."><plain>No treatment able to modify the disease progression is available </plain></SENT>
<SENT sid="3" pm="."><plain>However, gene silencing by <z:chebi fb="40" ids="33697">RNA</z:chebi> interference has shown promising results </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, in this study we investigated whether lentiviral-mediated allele-specific silencing of the mutant ataxin-3 gene, after disease <z:hpo ids='HP_0003674'>onset</z:hpo>, would rescue the motor behavior deficits and neuropathological features in a severely impaired transgenic mouse model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>For this purpose, we injected lentiviral vectors encoding allele-specific silencing-sequences (shAtx3) into the cerebellum of diseased transgenic mice expressing the targeted C-variant of mutant ataxin-3 present in 70% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients </plain></SENT>
<SENT sid="6" pm="."><plain>This variation permits to discriminate between the <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant forms, maintaining the <z:mpath ids='MPATH_458'>normal</z:mpath> function of the <z:mp ids='MP_0002169'>wild-type</z:mp> allele and silencing only the mutant form </plain></SENT>
<SENT sid="7" pm="."><plain>Quantitative analysis of rotarod performance, footprint and activity patterns revealed significant and robust alleviation of gait, balance (average 3-fold increase of rotarod test time), locomotor and exploratory activity impairments in shAtx3-injected mice, as compared to control ones injected with shGFP </plain></SENT>
<SENT sid="8" pm="."><plain>An important improvement of neuropathology was also observed, regarding the number of intranuclear inclusions, calbindin and DARPP-32 immunoreactivity, fluorojade B and Golgi staining and molecular and granular layers thickness </plain></SENT>
<SENT sid="9" pm="."><plain>These data demonstrate for the first time the efficacy of gene silencing in blocking the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>-associated motor-behavior and neuropathological abnormalities after the <z:hpo ids='HP_0003674'>onset</z:hpo> of the disease, supporting the use of this strategy for therapy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
</text></document>